Actionable news
0
All posts from Actionable news
Actionable news in BBC: BIOSHARES BIOTECHNOLOGY CLINICAL TRIALS FUND,

Two ETF Plays for a Rebound in Biotech Stocks

The lack of major drug launches last year, along with disappointing quarterly results from the likes of Biogen (BIIB - Get Report) , Celgene (CELG - Get Report) and Gilead (GILD - Get Report) , dragged down biotech stocks last year. The downtrend has continued into 2016, but the turn could soon be at hand, said Paul Yook, portfolio manager for BioShares BioTechnology ETFs.

Jim Cramer's Action Alerts PLUS, a charitable trust, owns Biogen in its portfolio.

"When you have a lack of big launches and you have missed earnings, that's going to depress the sector," said Yook.

According to Yook, the three key issues that pulled biotech down starting in mid-summer 2015 were largely disappointing major clinical trials, a record low number of...


More